Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02078245|
Recruitment Status : Recruiting
First Posted : March 5, 2014
Last Update Posted : March 27, 2018
Early detection of pre-cancerous lesions or early stage pancreatic cancer seems to have a positive impact in survival for patients with an increased genetic risk to develop pancreas cancer.
In this study, following the indication of the swedish guidelines, consecutive patients with a family history for pancreas cancer underwent a clinical surveillance Magnetic Resonance Imaging (MRI) based. The results of this study were analyzed looking in the patients files collected during the screening period.
|Condition or disease||Intervention/treatment|
|Hereditary Pancreatitis Hereditary Pancreatic Cancer||Other: MRI|
Show Detailed Description
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||100 participants|
|Target Follow-Up Duration:||15 Years|
|Official Title:||Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer|
|Study Start Date :||August 2010|
|Estimated Primary Completion Date :||January 2025|
|Estimated Study Completion Date :||January 2025|
Familial pancreatic cancer patients
Individual with ten fold higher risk to develop pancreatic cancer.
- MRI accuracy [ Time Frame: Three years ]MRI accuracy in detection precancerous pancreatic lesions.
- Definition of spectrum of precancerous pancreatic lesions [ Time Frame: During three years ]
- Outcome of surveillance program [ Time Frame: Three years ]Outcome of surveillance program analysis
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02078245
|Contact: Matthias Löhr, Professor||+46 email@example.com|
|Contact: Marco del Chiaro, Ass prof.||+46 firstname.lastname@example.org|
|Gastrocentrum Karolinska University Hospital||Recruiting|
|Stockholm, Sweden, 14186|
|Contact: Matthias Löhr, Professor 08-585800000 email@example.com|
|Contact: Marco del Chiaro, ass prof. 08-585800000 firstname.lastname@example.org|
|Principal Investigator: Matthias Lohr, Professor|
|Principal Investigator:||Marco del Chiaro, ass. prof.||Karolinska University Hospital|